Abstract:Small animal fluorescence molecular imaging (FMI) can be a powerful tool for preclinical drug discovery and development studies. However, light absorption by tissue chromophores (e.g., hemoglobin, water, lipids, melanin) typically limits optical signal propagation through thicknesses larger than a few millimeters. Compared to other visible wavelengths, tissue absorption for red and near-infrared (near-IR) light absorption dramatically decreases and non-elastic scattering becomes the dominant light-tissue interaction mechanism. The relatively recent development of fluorescent agents that absorb and emit light in the near-IR range (600-1000 nm), has driven the development of imaging systems and light propagation models that can achieve whole body three-dimensional imaging in small animals. Despite great strides in this area, the ill-posed nature of diffuse fluorescence tomography remains a significant problem for the stability, contrast recovery and spatial resolution of image reconstruction techniques and the optimal approach to FMI in small animals has yet to be agreed on. The majority of research groups have invested in charge-coupled device (CCD)-based systems that provide abundant tissue-sampling but suboptimal sensitivity, while our group and a few others have pursued systems based on very high sensitivity detectors, that at this time allow dense tissue sampling to be achieved only at the cost of low imaging throughput. Here we demonstrate the methodology for applying single-photon detection technology in a fluorescence tomography system to localize a cancerous brain lesion in a mouse model. The fluorescence tomography (FT) system employed single photon counting using photomultiplier tubes (PMT) and information-rich time-domain light detection in a non-contact conformation. This provides a simultaneous collection of transmitted excitation and emission light, and includes automatic fluorescence excitation exposure control, laser referencing, and co-registration with a small animal computed tomography (microCT) system. A nude mouse model was used for imaging. The animal was inoculated orthotopically with a human glioma cell line (U251) in the left cerebral hemisphere and imaged 2 weeks later. The tumor was made to fluoresce by injecting a fluorescent tracer, IRDye 800CW-EGF (LI-COR Biosciences, Lincoln, NE) targeted to epidermal growth factor receptor, a cell membrane protein known to be overexpressed in the U251 tumor line and many other cancers. A second, untargeted fluorescent tracer, Alexa Fluor 647 (Life Technologies, Grand Island, NY) was also injected to account for non-receptor mediated effects on the uptake of the targeted tracers to provide a means of quantifying tracer binding and receptor availability/density. A CT-guided, time-domain algorithm was used to reconstruct the location of both fluorescent tracers (i.e., the location of the tumor) in the mouse brain and their ability to localize the tumor was verified by contrast-enhanced magnetic resonance imaging. Though demonstrated for fluorescence imaging in a glioma mouse model, the methodology presented in this video can be extended to different tumor models in various small animal models potentially up to the size of a rat.

Monitoring Of Tumor Response To Cisplatin By Subsurface Fluorescence Molecular Tomography

Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Phosphorescence Monitoring of Hypoxic Microenvironment in Solid-Tumors to Evaluate Chemotherapeutic Effects Using the Hypoxia-Sensitive Iridium (III) Coordination Compound.

Monitoring of Tumor Response to Au Nanorod-Indocyanine Green Conjugates Mediated Therapy with Fluorescence Imaging and Positron Emission Tomography

Dual-modality monitoring of tumor response to cyclophosphamide therapy in mice with bioluminescence imaging and small-animal positron emission tomography.

A Semi-Automatic Validation Tool for Whole Mouse Metastatic Tumor Molecular Imaging Using the Cryo-Imaging Cancer Imaging and Therapy Platform (CITP)

Ultrasensitive Optical Detection and Elimination of Residual Microtumors with a Postoperative Implantable Hydrogel Sensor for Preventing Cancer Recurrence.

Feasibility of Monitoring Tumor Response by Tracking Nanoparticle-Labelled T Cells Using X-ray Fluorescence Imaging—A Numerical Study

Monitoring Response To Gefitinib In Nude Mouse Tumor Xenografts By F-18-Fdg Micropet-Ct: Correlation Between F-18-Fdg Uptake And Pathological Response

Concurrent fluorescence and volumetric optoacoustic tomography of nanoagent perfusion and bio-distribution in solid tumors

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Subsurface Fluorescence Molecular Tomography with Prior Information.

Monitoring Anti-Angiogenic Therapy Response in Mouse U87MG Tumor Model Using 18F-FLT and 18F-FDG Micropet/ct

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Tissue pO2 distributions in xenograft tumors dynamically imaged by Cherenkov-excited phosphorescence during fractionated radiation therapy

Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers

Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging

In Vivo Tomographic Imaging of Lung Colonization of Tumour in Mouse with Simultaneous Fluorescence and X‐ray CT

A Smart Responsive Fluorescence‐MR Nanoprobe for Monitoring Tumor Response to Immunotherapy

Water-Soluble Fluorescent Sensors for Quantification of Trace Cisplatin in Body Fluids from Clinical Cancer Patients